Humana shares drop amid Medicare reimbursement proposal concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy HUM?
Source: SeekingAlpha
Humana Inc. (NYSE:HUM) shares fell 17.31% in pre-market trading, hitting a 20-day low, following concerns over the Trump administration's proposal for nearly flat Medicare reimbursement rates for 2027.
The proposal indicates an average payment increase of only 0.09%, significantly below the anticipated 4%-6% rise, which raises revenue pressure on insurers like Humana. This has led to a decline in investor confidence, as the market reacted negatively to the potential impact on future profitability. Additionally, the Centers for Medicare & Medicaid Services (CMS) projects a payment change of only 2.54%, which also falls short of market expectations, further contributing to the stock's decline.
The implications of this proposal could be significant for Humana and other health insurers, as it reflects ongoing financial pressures in the sector. Investors are closely monitoring the situation, as the flat reimbursement rates could hinder growth and profitability in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 173.620
Low
231.00
Averages
290.39
High
344.00
Current: 173.620
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Completes $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Planned Use of Proceeds: The company intends to use the net proceeds from this bond offering for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby optimizing financial leverage and reducing interest expenses.
- Underwriter Lineup: The bond offering was jointly managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence in Humana's debt instruments.
- Compliance and Forward-Looking Statements: This offering was made pursuant to an effective registration statement with the SEC, and Humana has issued forward-looking statements to alert investors to potential operational risks and uncertainties, ensuring transparency and compliance.
See More
U.S. HMO Industry Faces Challenges and Opportunities
- Rising Medical Costs: U.S. health insurers are experiencing increased medical expenses due to the resumption of deferred care and heightened demand for chronic disease management, leading to a rise in insurance claims and pressure on profit margins.
- Regulatory Uncertainty: New legislation may tighten Medicaid eligibility and reduce ACA enrollment, impacting insurers' membership and reimbursements, which forces a shift towards commercial insurance products to enhance profitability.
- Healthcare Workforce Shortage: The ongoing shortage of nurses and healthcare professionals is straining hospital operations, affecting HMOs' ability to deliver high-quality care, which could lead to customer attrition.
- M&A Strategy: HMO companies are pursuing mergers and acquisitions to expand market share and enhance competitiveness, with expected interest rate declines in 2026 likely to fuel further M&A activity, driving industry consolidation.
See More
Congressional Investigation Reveals Medicare Overpayment Issues
- Medicare Overpayment Investigation: The Joint Economic Committee's investigation revealed that alleged overpayments to Medicare Advantage plans resulted in a $13.4 billion increase in Medicare Part B premiums last year, primarily impacting seniors, highlighting potential financial pressures within the Medicare system.
- Premium Hike Impact: The investigation found that the average Medicare premium for American seniors rose by approximately 10%, equating to over $200 annually, directly affecting beneficiaries of both Medicare Advantage and standard Medicare, indicating a pressing need for policy adjustments.
- Insurer Rebuttal: America's Health Insurance Plans (AHIP), representing health insurers, denied the investigation's findings, claiming they were based on “fundamentally flawed data and methodology,” illustrating the industry's strong opposition to policy changes and potential conflicts of interest.
- Market Participant Overview: UnitedHealth (UNH) stands as the largest player in the Medicare Advantage market, followed by Humana (HUM) and others, underscoring the significant role and influence of major insurers in the evolving landscape of Medicare policy.
See More
Humana Completes $1 Billion Junior Subordinated Notes Offering
- Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, with expected net proceeds of approximately $986 million, which will be used for general corporate purposes including repayment of existing debt, thereby enhancing financial flexibility.
- Underwriter Lineup: The offering was managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence and support for Humana.
- Compliance and Transparency: The issuance was conducted under an effective shelf registration statement with the SEC, ensuring compliance and transparency, which may attract more investors for future financing activities.
- Future Outlook: Humana intends to leverage this financing to improve its capital structure, particularly in the highly competitive healthcare sector, thereby strengthening its market position and financial stability to address future challenges and opportunities.
See More
AM Best Assigns Long-Term Credit Rating to Humana
- Credit Rating Upgrade: AM Best has assigned a 'bbb-' Long-Term Credit Rating to Humana Inc.'s $1 billion, 6.625% fixed-rate junior subordinated notes, with a stable outlook, indicating the company's solid creditworthiness in financing.
- Financial Leverage Changes: The issuance is expected to slightly increase Humana's financial leverage to approximately 41.8% by year-end 2025, exceeding the long-term target of 40%, but management aims to manage this through equity increases and continued deleveraging.
- Liquidity Support: Humana's cash flow in 2025 totaled $0.9 billion, a significant drop from $3 billion in 2024, driven by timing impacts and increased receivables, yet the company maintains good liquidity through $1.1 billion in dividends from subsidiaries and $5 billion in credit lines.
- Profitability Trends: While Humana achieved strong premium growth in 2025, primarily from its Medicare Advantage segment, net income was impacted by increased utilization and changes in reimbursement, with expectations for positive earnings but margin compression throughout 2026.
See More
Humana Prices $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
- Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
- Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
See More
Humana Completes $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Planned Use of Proceeds: The company intends to use the net proceeds from this bond offering for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby optimizing financial leverage and reducing interest expenses.
- Underwriter Lineup: The bond offering was jointly managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence in Humana's debt instruments.
- Compliance and Forward-Looking Statements: This offering was made pursuant to an effective registration statement with the SEC, and Humana has issued forward-looking statements to alert investors to potential operational risks and uncertainties, ensuring transparency and compliance.
See More
U.S. HMO Industry Faces Challenges and Opportunities
- Rising Medical Costs: U.S. health insurers are experiencing increased medical expenses due to the resumption of deferred care and heightened demand for chronic disease management, leading to a rise in insurance claims and pressure on profit margins.
- Regulatory Uncertainty: New legislation may tighten Medicaid eligibility and reduce ACA enrollment, impacting insurers' membership and reimbursements, which forces a shift towards commercial insurance products to enhance profitability.
- Healthcare Workforce Shortage: The ongoing shortage of nurses and healthcare professionals is straining hospital operations, affecting HMOs' ability to deliver high-quality care, which could lead to customer attrition.
- M&A Strategy: HMO companies are pursuing mergers and acquisitions to expand market share and enhance competitiveness, with expected interest rate declines in 2026 likely to fuel further M&A activity, driving industry consolidation.
See More
Congressional Investigation Reveals Medicare Overpayment Issues
- Medicare Overpayment Investigation: The Joint Economic Committee's investigation revealed that alleged overpayments to Medicare Advantage plans resulted in a $13.4 billion increase in Medicare Part B premiums last year, primarily impacting seniors, highlighting potential financial pressures within the Medicare system.
- Premium Hike Impact: The investigation found that the average Medicare premium for American seniors rose by approximately 10%, equating to over $200 annually, directly affecting beneficiaries of both Medicare Advantage and standard Medicare, indicating a pressing need for policy adjustments.
- Insurer Rebuttal: America's Health Insurance Plans (AHIP), representing health insurers, denied the investigation's findings, claiming they were based on “fundamentally flawed data and methodology,” illustrating the industry's strong opposition to policy changes and potential conflicts of interest.
- Market Participant Overview: UnitedHealth (UNH) stands as the largest player in the Medicare Advantage market, followed by Humana (HUM) and others, underscoring the significant role and influence of major insurers in the evolving landscape of Medicare policy.
See More
Humana Completes $1 Billion Junior Subordinated Notes Offering
- Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, with expected net proceeds of approximately $986 million, which will be used for general corporate purposes including repayment of existing debt, thereby enhancing financial flexibility.
- Underwriter Lineup: The offering was managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence and support for Humana.
- Compliance and Transparency: The issuance was conducted under an effective shelf registration statement with the SEC, ensuring compliance and transparency, which may attract more investors for future financing activities.
- Future Outlook: Humana intends to leverage this financing to improve its capital structure, particularly in the highly competitive healthcare sector, thereby strengthening its market position and financial stability to address future challenges and opportunities.
See More
AM Best Assigns Long-Term Credit Rating to Humana
- Credit Rating Upgrade: AM Best has assigned a 'bbb-' Long-Term Credit Rating to Humana Inc.'s $1 billion, 6.625% fixed-rate junior subordinated notes, with a stable outlook, indicating the company's solid creditworthiness in financing.
- Financial Leverage Changes: The issuance is expected to slightly increase Humana's financial leverage to approximately 41.8% by year-end 2025, exceeding the long-term target of 40%, but management aims to manage this through equity increases and continued deleveraging.
- Liquidity Support: Humana's cash flow in 2025 totaled $0.9 billion, a significant drop from $3 billion in 2024, driven by timing impacts and increased receivables, yet the company maintains good liquidity through $1.1 billion in dividends from subsidiaries and $5 billion in credit lines.
- Profitability Trends: While Humana achieved strong premium growth in 2025, primarily from its Medicare Advantage segment, net income was impacted by increased utilization and changes in reimbursement, with expectations for positive earnings but margin compression throughout 2026.
See More
Humana Prices $1 Billion Junior Subordinated Notes Offering
- Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
- Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
- Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
- Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
See More
